Monopar Therapeutics Inc
NASDAQ:MNPR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Other Current Assets
Monopar Therapeutics Inc
Other Current Assets Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Other Current Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
Other Current Assets
$119k
|
CAGR 3-Years
3%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$4.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$2.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$511.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Assets
$414.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Monopar Therapeutics Inc's Other Current Assets?
Other Current Assets
119k
USD
Based on the financial report for Mar 31, 2024, Monopar Therapeutics Inc's Other Current Assets amounts to 119k USD.
What is Monopar Therapeutics Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-24%
Over the last year, the Other Current Assets growth was 8%. The average annual Other Current Assets growth rates for Monopar Therapeutics Inc have been 3% over the past three years , -24% over the past five years .
You don't have any saved screeners yet
